证券代码：920992 证券简称：中科美菱 公告编号：2025-126 中科美菱低温科技股份有限公司 关于使用自有闲置资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、授权自有资金理财情况 （一）购买理财产品的审议情况 为提高公司资金使用效益，增加现金资产收益，实现股东利益最大化，公司 第三届董事会第三十一次会议、2024 年第二次临时股东大会，审议通过了《关 于使用自有闲置资金进行投资理财的议案》，在保证日常经营运作资金需求、有 效控制投资风险的前提下，公司及下属子公司拟使用自有闲置资金最高不超过 2 亿元人民币（该额度可以滚动使用）进行银行理财产品投资，投资期限为自 2024 年第二次临时股东大会审议通过之日起一年内有效。 具体内容详见公司于 2024 年 12 月 11 日、12 月 27 日在北京证券交易所网 站披露的《关于使用自有闲置资金进行投资理财的公告》（公告编号：2024-071）、 《2024 年第二次临时股东大会决议公告》（公告编号：2024-074）。 ...

证券代码：920992 证券简称：中科美菱 公告编号：2025-125 中科美菱低温科技股份有限公司 关于使用自有闲置资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、授权自有资金理财情况 （一）购买理财产品的审议情况 为提高公司资金使用效益，增加现金资产收益，实现股东利益最大化，公司 第三届董事会第三十一次会议、2024 年第二次临时股东大会，审议通过了《关 于使用自有闲置资金进行投资理财的议案》，在保证日常经营运作资金需求、有 效控制投资风险的前提下，公司及下属子公司拟使用自有闲置资金最高不超过 2 亿元人民币（该额度可以滚动使用）进行银行理财产品投资，投资期限为自 2024 年第二次临时股东大会审议通过之日起一年内有效。 | 受托方 | 产品 | 产品 | 产品金额 | 预计年化收 | 产品期 | 收益 | 投资 | 资金 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 类型 | 名称 ...

证券代码：920992 证券简称：中科美菱 公告编号：2025-123 1.基本信息 中科美菱低温科技股份有限公司 关于变更签字注册会计师的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 中科美菱低温科技股份有限公司（以下简称公司）分别于 2025 年 3 月 20 日、2025 年 4 月 11 日召开了第三届董事会第三十四次会议和 2024 年年度股东 大会，审议通过了《关于拟续聘 2025 年度会计师事务所的议案》，同意续聘天健 会计师事务所(特殊普通合伙)作为公司 2025 年度财务报告、内部控制审计机构， 聘任期限一年。具体内容详见公司于 2025 年 3 月 21 日、4 月 11 日在北京证券 交易所网站披露的《拟续聘 2025 年度会计师事务所公告》（公告编号：2025-016）、 《2024 年年度股东大会决议公告》（公告编号：2025-032）。 2025 年 10 月 30 日，公司收到天健会计师事务所(特殊普通合伙)出具的《关 于变更签字注册会计师的函》，现将有关情况公告如 ...

证券代码：920992 证券简称：中科美菱 公告编号：2025-124 中科美菱低温科技股份有限公司 股票解除限售公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、本次股票解除限售数量总额为 19,500,000 股，占公司总股本 20.1590%， 可交易时间为 2025 年 11 月 6 日。 E 公开发行前特定主体股票解除限售 F 参与战略配售取得股票解除限售 G 其他（说明具体原因） | 序号 | 股东姓名或 | 是否为 控股股 东、实 际控制 | | 本次 | 本次解除限 售登记股票 | 本次解除 | 尚未解 除限售 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 任职情 | 解限 | | 限售股数 | | | | 名称 | 人或其 | 况 | 售原 | 数量 | 占公司总 | 的股票 | | | | | | 因 | | 股本比例 | 数量 | | | | 一致行 | | | | | | | | | 动人 | | ...

Investment Rating - The investment rating for the company is "Accumulate" (first coverage) [1][7] Core Viewpoints - The company is a pioneer in the field of ultra-low temperature storage for biological cells in China, backed by Changhong Group and supported by the Chinese Academy of Sciences. It has developed several industry-leading products, including ultra-low temperature storage boxes reaching -180°C, and has a strong patent portfolio with 436 patents as of the end of 2024 [4][7][21]. - The company has shown stable revenue growth, with a projected revenue of 320.91 million yuan in 2025, reflecting an 8.50% increase year-on-year. The net profit is expected to reach 25.22 million yuan, a 39.43% increase [5][7]. - The domestic medical device market is projected to grow significantly, with the market size expected to exceed 1.8 trillion yuan by 2030, and the biological low-temperature storage equipment market is anticipated to grow from 6.772 billion yuan in 2022 to 21.543 billion yuan by 2028 [7][9]. Company Overview - The company, established in 2002, has developed a diverse product portfolio in the ultra-low temperature storage sector, including products that operate in the temperature range of -196°C to 8°C, widely used in medical, research, and biopharmaceutical fields [13][28]. - The company has received numerous accolades, including being recognized as a national-level "specialized and innovative" small giant enterprise and has won various awards for technological innovation [17][21]. Financial Forecast - The financial forecast indicates total revenue of 302.79 million yuan in 2023, with a decline of 25.51%, followed by a slight recovery in 2024 to 295.77 million yuan. The company is expected to achieve a revenue of 320.91 million yuan in 2025, with a growth rate of 8.50% [5][7]. - The projected net profit for 2025 is 25.22 million yuan, representing a significant increase of 39.43% compared to 2024 [5][7]. Industry Analysis - The medical device industry is experiencing rapid growth, driven by various factors, including policy support and increasing demand for domestic medical equipment. The company is well-positioned to benefit from these trends as a leading player in the biological low-temperature storage market [9][28]. - The company has a competitive edge in the market, having ranked among the top three domestic brands in low-temperature storage equipment, and is expected to capture more market share due to its technological advantages [29][40].

Investment Rating - The investment rating for the company is "Accumulate" (首次) [1][9] Core Insights - The company is a pioneer in the field of ultra-low temperature storage for biological cells, breaking foreign monopolies and focusing on technological innovation and market expansion [6][30] - The company has achieved a revenue of 1.5 billion yuan in the first half of 2025, with a year-on-year growth of 2.16%, and a net profit of 11.05 million yuan, reflecting a 5.94% increase [9][31] - The domestic medical device market is projected to reach 1.35 trillion yuan in 2024, with a compound annual growth rate of 7.53% from 2025 to 2030 [9][31] Company Overview - The company, established in 2002, is backed by Changhong Group and supported by the Chinese Academy of Sciences, focusing on ultra-low temperature storage [9][15] - It has received numerous accolades, including being recognized as a national-level "Little Giant" enterprise and winning the National Technology Invention Award [19][23] - The company has a diverse product portfolio, including ultra-low temperature storage boxes and laboratory equipment, with applications in medical, research, and biopharmaceutical fields [30][31] Financial Performance - Revenue projections for 2025-2027 are 320.91 million, 356.79 million, and 406.46 million yuan, with respective growth rates of 8.50%, 11.18%, and 13.92% [7][9] - The net profit for the same period is expected to be 25.22 million, 29.55 million, and 32.70 million yuan, with growth rates of 39.43%, 17.19%, and 10.64% [7][9] - The company's gross margin is reported at 36.67%, with a net margin of 7.35% for the first half of 2025 [9][31] Industry Analysis - The medical device industry is driven by policy and demand, with a significant push for domestic alternatives [11][30] - The market for biological low-temperature storage equipment is expected to grow from 6.772 billion yuan in 2022 to 21.543 billion yuan by 2028 [9][31] - The company is positioned to benefit from increasing demand for medical equipment in rural areas and supportive government policies [9][31] Product and Technology - The company has developed a comprehensive range of products, including ultra-low temperature storage devices and laboratory equipment, covering temperature ranges from -196°C to 8°C [30][31] - It has a strong focus on R&D, with 11.19% of revenue allocated to research, resulting in 436 patents as of the end of 2024 [9][45] - The company aims to enhance its technological capabilities and expand its product offerings in the ultra-low temperature storage sector [42][45]

证券代码：920992 证券简称：中科美菱 公告编号：2025-122 中科美菱低温科技股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、投资者关系活动类别 √特定对象调研 □业绩说明会 参会单位及人员：信达澳银基金、天弘基金管理有限公司、创金合信基金管 理有限公司、高盛工银理财有限责任公司、方正富邦基金管理有限公司、开源证 券股份有限公司、东北证券股份有限公司、民生证券股份有限公司、建信理财有 限责任公司、深圳市国晖投资有限公司、绍兴冰剑投资管理有限公司、上海赛伯 乐投资有限公司、上海睿源私募基金管理有限公司、上海九祥资产管理有限公司、 果实资本、广州市罗爵资产管理有限公司、广东正圆私募基金管理有限公司、点 石成鑫资产管理有限公司、大湾区发展基金管理有限公司、北京星允投资管理有 限公司、北京青创伯乐投资有限公司、涌德瑞烜(上海)私募基金管理有限公司 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 二、投资者关系活动情况 活动时间：2025 ...

Core Insights - The medical device sector experienced a slight increase of 0.37% on October 24, with Mai Lande leading the gains [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Medical Device Sector Performance - Top gainers included: - Mai Lande (688273) with a closing price of 41.92, up 6.31%, trading volume of 29,300 hands, and a transaction value of 121 million yuan [1] - Xiangyu Medical (688626) at 53.21, up 6.10%, with a trading volume of 41,100 hands and a transaction value of 216 million yuan [1] - Xiangsheng Medical (688358) at 35.27, up 4.75%, with a trading volume of 38,400 hands and a transaction value of 136 million yuan [1] - Other notable gainers included: - Aohua Endoscopy (688212) at 50.59, up 4.74%, with a transaction value of 225 million yuan [1] - Weisi Medical (688580) at 49.10, up 4.71%, with a transaction value of approximately 99.8 million yuan [1] Decliners in Medical Device Sector - Notable decliners included: - Chenguang Medical (920300) at 17.51, down 8.80%, with a trading volume of 124,000 hands [2] - Toukeng Life (300642) at 22.95, down 5.40%, with a trading volume of 175,700 hands [2] - Haitai New Light (688677) at 48.50, down 5.05%, with a trading volume of 38,800 hands [2] - Other significant decliners included: - Sino Medical (688108) at 28.00, down 4.73%, with a trading volume of 263,700 hands [2] - Tianchen Medical (688013) at 55.66, down 3.98%, with a trading volume of 19,200 hands [2] Capital Flow in Medical Device Sector - The medical device sector saw a net outflow of 654 million yuan from major funds, while retail investors contributed a net inflow of 455 million yuan [2]

Core Viewpoint - The report indicates that Zhongke Meiling (stock code: 920992) has shown a slight decrease in total assets but an increase in net assets and profitability for the third quarter of 2025 compared to the previous year [3][7]. Financial Data Summary - Total assets as of September 30, 2025, amounted to 727.28 billion, a decrease of 2.41% from 745.28 billion at the end of 2024 [7]. - Net assets attributable to shareholders increased to 618.40 billion, reflecting a growth of 1.09% from 611.74 billion [7]. - The asset-liability ratio for the parent company was 14.18%, down from 16.43%, while the consolidated asset-liability ratio decreased from 17.92% to 14.97% [7]. - Revenue for the first nine months of 2025 reached 224.39 billion, up 4.75% from 214.21 billion in the same period of 2024 [7]. - Net profit attributable to shareholders was 12.76 billion, an increase of 8.19% compared to 11.79 billion [7]. - Basic earnings per share rose to 0.1319 yuan, reflecting an increase of 8.20% from 0.1219 yuan [7]. Cash Flow and Profitability - The net cash flow from operating activities for the first nine months was 3.90 billion, showing a slight decrease of 0.07% from 3.90 billion in the previous year [7]. - The weighted average return on equity based on net profit attributable to shareholders was 2.07%, up from 1.95% [7]. - The weighted average return on equity based on net profit after deducting non-recurring gains and losses increased significantly from 0.44% to 1.06% [7]. Quarterly Performance - For the third quarter of 2025, revenue was 74.16 billion, a growth of 10.44% from 67.15 billion in the same quarter of 2024 [7]. - Net profit attributable to shareholders for the third quarter was 1.71 billion, a substantial increase of 25.42% from 1.36 billion [7]. - The basic earnings per share for the third quarter rose to 0.0177 yuan, an increase of 25.53% from 0.0141 yuan [7]. Major Changes in Financial Data - Cash and cash equivalents decreased by 40.96% to 340.08 billion due to the management of idle funds [9]. - Accounts receivable increased by 223.30% to 9.90 billion, attributed to increased sales during the credit period [9]. - Contract liabilities decreased by 40.10% to 10.89 billion, primarily due to revenue recognition from previous contracts [9]. - Tax payable decreased by 35.80% to 1.66 billion, reflecting a reduction in value-added tax and additional taxes [9]. Shareholder Structure - The total number of ordinary shares at the end of the reporting period was 96.73 billion, with 5,496 shareholders [12]. - The largest shareholder, Changhong Meiling Co., Ltd., holds 45.90 billion shares, representing 47.45% of the total [12]. - The second-largest shareholder, Zhongke Xianxing (Beijing) Asset Management Co., Ltd., holds 19.50 billion shares, accounting for 20.16% [12].

证券代码：920992 证券简称：中科美菱 公告编号：2025-120 中科美菱低温科技股份有限公司 第四届董事会第六次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 10 月 22 日 2.会议召开地点：公司会议室 6.会议列席人员：公司董事会秘书及其他高级管理人员 7.召开情况合法合规的说明： 本次会议的召集、召开、议案审议程序等符合有关法律、行政法规、部门 规章、规范性文件和《公司章程》的有关规定。 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 二、议案审议情况 （一）审议通过《2025 年第三季度报告》 1.议案内容： 3.会议召开方式：通讯方式 4.发出董事会会议通知的时间和方式：2025 年 10 月 20 日以电子邮件方式发 出 5.会议主持人：董事长吴定刚先生 根据公司业务发展以及经营管理的需要，同意公司向中国民生银行股份有 限公司合肥分行申请 3000 万元人民币最高授 ...